Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.30) per share for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.10) EPS, FY2029 earnings at ($0.26) EPS and FY2030 earnings at $1.51 EPS.

Several other analysts also recently issued reports on NMRA. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday. Mizuho set a $6.00 price target on Neumora Therapeutics in a research report on Monday, January 5th. Leerink Partners began coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price for the company. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Neumora Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Neumora Therapeutics Trading Up 7.2%

NMRA opened at $2.09 on Thursday. The stock has a market capitalization of $380.46 million, a P/E ratio of -1.44 and a beta of 3.08. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The firm’s fifty day simple moving average is $2.74 and its 200 day simple moving average is $2.32.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).

Insider Buying and Selling at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the sale, the insider directly owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 23,387 shares of company stock valued at $82,647 in the last three months. 26.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Legacy Private Trust Co. acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at approximately $25,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics in the 4th quarter valued at $27,000. Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics during the 3rd quarter worth $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics during the 4th quarter worth $40,000. Finally, Canada Pension Plan Investment Board acquired a new position in Neumora Therapeutics during the second quarter worth about $41,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.